{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:56:27Z","timestamp":1773230187839,"version":"3.50.1"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.pharmthera.2015.12.008","type":"journal-article","created":{"date-parts":[[2015,12,20]],"date-time":"2015-12-20T09:45:20Z","timestamp":1450604720000},"page":"114-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Lymphangioleiomyomatosis: Current understanding and potential treatments"],"prefix":"10.1016","volume":"158","author":[{"given":"Lyn M.","family":"Moir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2015.12.008_bb0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.crad.2011.02.009","article-title":"Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex","volume":"66","author":"Adriaensen","year":"2011","journal-title":"Clin Radiol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jcb.24997","article-title":"The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells","volume":"116","author":"Alayev","year":"2015","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0015","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4161\/cc.27355","article-title":"Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells","volume":"13","author":"Alayev","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.resinv.2013.03.002","article-title":"The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis","volume":"51","author":"Ando","year":"2013","journal-title":"Respir Invest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0025","first-page":"02015","article-title":"Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis (LAM)","volume":"00262","author":"Atochina-Vasserman","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0030","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1165\/rcmb.2013-0203RC","article-title":"Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling","volume":"49","author":"Atochina-Vasserman","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1164\/ajrccm.162.2.9911006","article-title":"Pulmonary lymphangioleiomyomatosis in a man","volume":"162","author":"Aubry","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0040","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.rmed.2013.08.045","article-title":"A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM","volume":"107","author":"Baldi","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0045","doi-asserted-by":"crossref","first-page":"e105365","DOI":"10.1371\/journal.pone.0105365","article-title":"A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM)","volume":"9","author":"Banville","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0050","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0974-7796.148664","article-title":"A case of recurrent retroperitoneal lymphangioleiomyomatosis treated with progesterone therapy","volume":"7","author":"Basnet","year":"2015","journal-title":"Urol Ann"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/ajcp\/93.5.609","article-title":"Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study","volume":"93","author":"Berger","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-4020-6554-5_9","article-title":"Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development","volume":"615","author":"Bialik","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0070","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/hupa.2003.50","article-title":"Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis","volume":"34","author":"Bittmann","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1164\/rccm.200904-0631OC","article-title":"Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness","volume":"181","author":"Burgess","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0085","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201003-0489OC","article-title":"Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis","volume":"182","author":"Cai","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2015.12.008_bb0765","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1378\/chest.13-1071","article-title":"Sirolimus decreases circulating LAM cells in patients with lymphangioleiomyomatosis","volume":"145","author":"Cai","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0095","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis","volume":"97","author":"Carsillo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1465-9921-13-34","article-title":"Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis","volume":"13","author":"Chang","year":"2012","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0105","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1183\/09031936.00167413","article-title":"A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis","volume":"43","author":"Chang","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0110","doi-asserted-by":"crossref","first-page":"L393","DOI":"10.1152\/ajplung.00437.2009","article-title":"Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells","volume":"299","author":"Chang","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/modpathol.2008.189","article-title":"Cathepsin-k expression in pulmonary lymphangioleiomyomatosis","volume":"22","author":"Chilosi","year":"2009","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.pharmthera.2015.12.008_bb0770","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/annonc\/mdv144","article-title":"Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors","volume":"26","author":"Chiorean","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0125","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1378\/chest.115.4.1041","article-title":"Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis","volume":"115","author":"Chu","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1677\/ERC-08-0123","article-title":"Analysis of the oestrogen response in an angiomyolipoma derived xenograft model","volume":"16","author":"Clements","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.taap.2011.05.016","article-title":"Simvastatin induces apoptosis by a Rho-dependent mechanism in cultured cardiac fibroblasts and myofibroblasts","volume":"255","author":"Copaja","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4065\/75.6.591","article-title":"High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex","volume":"75","author":"Costello","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0145","doi-asserted-by":"crossref","first-page":"17462","DOI":"10.1073\/pnas.0407971101","article-title":"Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis","volume":"101","author":"Crooks","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0150","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0155","first-page":"1097","article-title":"Loss of type IV collagen alpha 5 and alpha 6 chains in human invasive prostate carcinomas","volume":"151","author":"Dehan","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0160","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1365-2133.2009.09098.x","article-title":"Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism","volume":"160","author":"Desai","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0165","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(03)13044-9","article-title":"Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma","volume":"361","author":"El-Hashemite","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0170","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Etienne-Manneville","year":"2002","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmthera.2015.12.008_bb0775","first-page":"1305","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"31;75","author":"European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0180","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1272\/jnms.67.311","article-title":"Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features","volume":"67","author":"Ferrans","year":"2000","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0185","doi-asserted-by":"crossref","first-page":"C409","DOI":"10.1152\/ajpcell.00482.2002","article-title":"Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression","volume":"285","author":"Finlay","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0190","doi-asserted-by":"crossref","first-page":"9878","DOI":"10.1158\/0008-5472.CAN-07-1394","article-title":"Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR\/S6 kinase activity","volume":"67","author":"Finlay","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0195","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1158\/1535-7163.MCT-09-0055","article-title":"Renal and liver tumors in Tsc2(+\/\u2212) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"8","author":"Finlay","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0200","doi-asserted-by":"crossref","first-page":"23114","DOI":"10.1074\/jbc.M401912200","article-title":"Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1\/2","volume":"279","author":"Finlay","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bjc.6600510","article-title":"Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters","volume":"87","author":"Fritz","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0210","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B","article-title":"Rho GTPases are over-expressed in human tumors","volume":"81","author":"Fritz","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0215","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.1074\/jbc.M900573200","article-title":"ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy","volume":"284","author":"Ganley","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0220","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00428-014-1559-9","article-title":"In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor","volume":"464","author":"Gao","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0230","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)","volume":"277","author":"Goncharova","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0780","doi-asserted-by":"crossref","first-page":"154ra134","DOI":"10.1126\/scitranslmed.3003840","article-title":"Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)","volume":"4","author":"Goncharova","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0240","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/MCB.01061-10","article-title":"mTORC2 is required for proliferation and survival of TSC2-null cells","volume":"31","author":"Goncharova","year":"2011","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1165\/rcmb.2005-0374OC","article-title":"Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0225","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1083\/jcb.200405130","article-title":"TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase","volume":"167","author":"Goncharova","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0250","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1165\/rcmb.2005-0300OC","article-title":"Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF03256240","article-title":"Relationship between matrix metalloproteinase 2 and lung cancer progression","volume":"11","author":"Guo","year":"2007","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0260","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0046-8177(97)90061-7","article-title":"Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM)","volume":"28","author":"Hayashi","year":"1997","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0265","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI58709","article-title":"Lymphangioleiomyomatosis\u2014A wolf in sheep's clothing","volume":"122","author":"Henske","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0270","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1055-9965.EPI-07-0531","article-title":"Statin induces apoptosis and cell growth arrest in prostate cancer cells","volume":"17","author":"Hoque","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0275","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1210\/endo.136.11.7588234","article-title":"Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo","volume":"136","author":"Howe","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0280","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0285","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2353\/ajpath.2006.050384","article-title":"Loss of expression of type IV collagen alpha5 and alpha6 chains in colorectal cancer associated with the hypermethylation of their promoter region","volume":"168","author":"Ikeda","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0290","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1083\/jcb.201102031","article-title":"Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells","volume":"193","author":"Inami","year":"2011","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0295","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.88.9.3628","article-title":"Cell cycle-specific effects of lovastatin","volume":"88","author":"Jakobisiak","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0785","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/MPA.0000000000000103","article-title":"The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion","volume":"43","author":"Je","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0310","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.2014.431","article-title":"In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells","volume":"111","author":"Jiang","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0305","first-page":"25","article-title":"Resveratrol downregulates PI3K\/Akt\/mTOR signaling pathways in human U251 glioma cells","volume":"8","author":"Jiang","year":"2009","journal-title":"J Exp Ther Oncol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0790","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/09031936.00076209","article-title":"European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis","volume":"35","author":"Johnson","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0320","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2004.023283","article-title":"Survival and disease progression in UK patients with lymphangioleiomyomatosis","volume":"59","author":"Johnson","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0325","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1183\/09031936.96.09112423","article-title":"Progesterone treatment in chylothorax associated with pulmonary tuberous sclerosis","volume":"9","author":"Jounieaux","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0330","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1091\/mbc.E08-12-1249","article-title":"ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery","volume":"20","author":"Jung","year":"2009","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0335","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1464-410x.2001.02030.x","article-title":"Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour","volume":"87","author":"Kamai","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0340","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/1078-0432.CCR-0436-03","article-title":"Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer","volume":"10","author":"Kamai","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0345","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1002\/cncr.24409","article-title":"Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma","volume":"115","author":"Kapoor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0350","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200208-969OC","article-title":"Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism","volume":"167","author":"Karbowniczek","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the Eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0360","first-page":"3602","article-title":"Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin","volume":"51","author":"Keyomarsi","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0365","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1164\/ajrccm.151.2.7842216","article-title":"Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors","volume":"151","author":"Kitaichi","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0370","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/01.pas.0000126859.70814.6d","article-title":"Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis","volume":"28","author":"Kumasaka","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0375","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.pas.0000172192.25295.45","article-title":"Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis","volume":"29","author":"Kumasaka","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0380","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1349-7006.2006.00242.x","article-title":"Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic cancer cell invasion and metastasis","volume":"97","author":"Kusama","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0385","first-page":"217","article-title":"Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho","volume":"29","author":"Kusama","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0390","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1749-6632.1994.tb24776.x","article-title":"The in vivo effect of doxycycline treatment on matrix metalloproteinases in reactive arthritis","volume":"732","author":"Lauhio","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0395","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/gcc.20357","article-title":"Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex","volume":"45","author":"Lee","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0400","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","article-title":"Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models","volume":"42","author":"Lee","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0410","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1165\/rcmb.2009-0050OC","article-title":"Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells","volume":"42","author":"Lee","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0405","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2210-9-8","article-title":"Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0415","doi-asserted-by":"crossref","first-page":"315240","DOI":"10.1155\/2015\/315240","article-title":"Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis","volume":"2015","author":"Lesma","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0420","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20131080","article-title":"Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells","volume":"211","author":"Li","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0425","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1165\/rcmb.2012-0476OC","article-title":"Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis","volume":"49","author":"Li","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1378\/chest.117.1.25","article-title":"Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis","volume":"117","author":"Logginidou","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0435","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0440","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.atherosclerosis.2009.07.033","article-title":"Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells","volume":"208","author":"Maeda","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0445","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0955-0674(03)00098-X","article-title":"Role of Rho-family proteins in cell adhesion and cancer","volume":"15","author":"Malliri","year":"2003","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0450","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5858\/2000-124-0267-RFAOMM","article-title":"Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis","volume":"124","author":"Matsui","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0455","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1165\/ajrcmb.21.3.3693","article-title":"Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis","volume":"21","author":"Matsumoto","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0795","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0465","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1164\/rccm.201205-0848OE","article-title":"Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm","volume":"186","author":"McCormack","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0470","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/path.1577","article-title":"Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis","volume":"203","author":"Merrilees","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0475","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2210-7-14","article-title":"Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779","volume":"7","author":"Messina","year":"2007","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5694\/mja12.11567","article-title":"Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis","volume":"199","author":"Mohammadieh","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0485","doi-asserted-by":"crossref","first-page":"L703","DOI":"10.1152\/ajplung.00414.2011","article-title":"TSC2 modulates cell adhesion and migration via integrin-alpha1beta1","volume":"303","author":"Moir","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0490","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1476-5381.2011.01344.x","article-title":"Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells","volume":"164","author":"Moir","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0495","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/187153008786848295","article-title":"SRC as a therapeutic target in breast cancer","volume":"8","author":"Morgan","year":"2008","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0500","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1056\/NEJMc053410","article-title":"Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs","volume":"354","author":"Moses","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0505","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1164\/ajrccm.186.4.389","article-title":"Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy","volume":"186","author":"Moua","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0510","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jmg.2008.065342","article-title":"TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex","volume":"46","author":"Muzykewicz","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0515","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/path.928","article-title":"Loss of alveolar basement membrane type IV collagen alpha3, alpha4, and alpha5 chains in bronchioloalveolar carcinoma of the lung","volume":"194","author":"Nakano","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0520","first-page":"281","article-title":"Differential tissular expression and localization of type IV collagen alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors","volume":"79","author":"Nakano","year":"1999","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0525","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1111\/jcmm.12593","article-title":"Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells\u2014effects on RhoA-GTPase and focal adhesion kinase","volume":"19","author":"Ng","year":"2015","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0530","first-page":"3263","article-title":"Expression of membrane-type matrix metalloproteinase in human gastric carcinomas","volume":"55","author":"Nomura","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0540","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.humpath.2009.12.009","article-title":"High levels of extracellular matrix metalloproteinase inducer are expressed in lymphangioleiomyomatosis","volume":"41","author":"Odajima","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0535","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0545","doi-asserted-by":"crossref","first-page":"10573","DOI":"10.1158\/0008-5472.CAN-07-1356","article-title":"TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis","volume":"67","author":"Pacheco-Rodriguez","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0550","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1073\/pnas.1104361108","article-title":"Tumorigenesis in tuberous sclerosis complex is autophagy and p62\/sequestosome 1 (SQSTM1)-dependent","volume":"108","author":"Parkhitko","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0555","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1590\/S1806-37132013000100002","article-title":"Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response","volume":"39","author":"Pimenta","year":"2013","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-5945-8-1","article-title":"Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model","volume":"8","author":"Rauktys","year":"2008","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0565","doi-asserted-by":"crossref","first-page":"e11941","DOI":"10.1371\/journal.pone.0011941","article-title":"Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3","volume":"5","author":"Rinderknecht","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0570","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0575","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.200610-1408CR","article-title":"Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex","volume":"176","author":"Schiavina","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0580","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0585","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1476-4598-5-45","article-title":"Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells","volume":"5","author":"Sexton","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0590","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/lrb.2009.0018","article-title":"Lymphangioleiomyomatosis: a disease involving the lymphatic system","volume":"8","author":"Seyama","year":"2010","journal-title":"Lymphat Res Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0595","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/lrb.2006.4.143","article-title":"Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis","volume":"4","author":"Seyama","year":"2006","journal-title":"Lymphat Res Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0600","doi-asserted-by":"crossref","first-page":"8694","DOI":"10.1158\/0008-5472.CAN-04-2247","article-title":"Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma","volume":"64","author":"Simpson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0605","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1086\/301804","article-title":"Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis","volume":"62","author":"Smolarek","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0610","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0620","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12672-014-0192-z","article-title":"Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis","volume":"5","author":"Sun","year":"2014","journal-title":"Horm Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0615","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.canlet.2009.05.004","article-title":"Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK)","volume":"285","author":"Sun","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0625","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1165\/rcmb.2006-0034OC","article-title":"Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin","volume":"35","author":"Takeda","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0800","doi-asserted-by":"crossref","first-page":"W292","DOI":"10.7326\/0003-4819-154-12-201106210-00007","article-title":"Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus","volume":"154","author":"Taveira-DaSilva","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0635","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1183\/09031936.00088314","article-title":"Severity and outcome of cystic lung disease in women with tuberous sclerosis complex","volume":"45","author":"Taveira-DaSilva","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0640","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/lrb.2009.0024","article-title":"The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis","volume":"8","author":"Taveira-DaSilva","year":"2010","journal-title":"Lymphat Res Biol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0645","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1378\/chest.09-0624","article-title":"Reversible airflow obstruction in lymphangioleiomyomatosis","volume":"136","author":"Taveira-DaSilva","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0650","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1378\/chest.126.6.1867","article-title":"Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone","volume":"126","author":"Taveira-DaSilva","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0655","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4161\/auto.5.5.8504","article-title":"Rapamycin inhibits mTORC1, but not completely","volume":"5","author":"Thoreen","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0660","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","article-title":"Mechanism of biological synergy between cellular Src and epidermal growth factor receptor","volume":"96","author":"Tice","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0665","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejrad.2014.12.008","article-title":"Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients","volume":"84","author":"Tobino","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0670","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-13-1256","article-title":"SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis","volume":"74","author":"Tyryshkin","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0675","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4161\/15384101.2014.986394","article-title":"Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy","volume":"14","author":"Valianou","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0680","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"van Slegtenhorst","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0685","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjp.0702668","article-title":"Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat\/cholesterol fed rabbits","volume":"127","author":"Verd","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0690","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0695","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1038\/srep07593","article-title":"Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion","volume":"4","author":"Warita","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0700","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/thx.2006.071811","article-title":"Lymphangioleiomyomatosis\u2014Presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets","volume":"62","author":"Watz","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0705","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1111\/j.1582-4934.2012.01648.x","article-title":"Lamstatin\u2014A novel inhibitor of lymphangiogenesis derived from collagen IV","volume":"16","author":"Weckmann","year":"2012","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0710","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1634\/theoncologist.2009-0009","article-title":"The role of Src in solid tumors","volume":"14","author":"Wheeler","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0715","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1158\/1078-0432.CCR-07-5232","article-title":"Statin-dependent suppression of the Akt\/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma","volume":"14","author":"Woodard","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0720","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0725","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201405-0918OC","article-title":"Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis","volume":"190","author":"Yao","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0730","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<139::AID-CNCR20>3.0.CO;2-4","article-title":"Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma","volume":"79","author":"Yoshizaki","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0735","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","article-title":"Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial","volume":"1","author":"Young","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0740","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.10-0573","article-title":"Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases","volume":"138","author":"Young","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0745","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1164\/ajrccm.164.8.2104095","article-title":"Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis","volume":"164","author":"Yu","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0750","doi-asserted-by":"crossref","first-page":"L694","DOI":"10.1152\/ajplung.00204.2003","article-title":"Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways","volume":"286","author":"Yu","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0755","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1073\/pnas.0810790106","article-title":"Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells","volume":"106","author":"Yu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2015.12.008_bb0760","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/0008-5472.CAN-07-6163","article-title":"Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy","volume":"68","author":"Zeng","year":"2008","journal-title":"Cancer Res"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581500234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581500234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T23:47:52Z","timestamp":1653868072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372581500234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":152,"alternative-id":["S016372581500234X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.12.008","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphangioleiomyomatosis: Current understanding and potential treatments","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2015.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}